当前位置： SCI文献检索 > Clinical Colorectal Cancer期刊下所有文献 > Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.

Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.

Abstract：

BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases remain largely unknown. PATIENTS AND METHODS:We reviewed the data from metastatic CRC (mCRC) patients who had received oxaliplatin- or irinotecan-based systemic chemotherapy from 2005 to 2016. The predictors for conversion to surgery were assessed by multivariate analyses. Cancer-free survival and overall survival after the initiation of treatment were compared between patients who had undergone successful conversion therapy and those who had undergone surgery first for resectable stage IV CRC. RESULTS:Of 99 mCRC patients receiving first-line chemotherapy, 23 underwent secondary surgical resection. Single organ metastasis, the presence of liver metastases, and the use of biologic agents were independent predictors of successful conversion therapy. The long-term survival of patients who underwent successful secondary surgery did not differ significantly from that of the 112 patients with resectable stage IV CRC who had undergone surgery first. CONCLUSION:Liver metastases and single organ metastasis were more likely to be resected after chemotherapy than were other metastatic lesions in mCRC. The use of biologic agents contributed to the increased conversion rate. Successful conversion resulted in outcomes similar to those of resectable stage IV CRC.

journal_name

Clin Colorectal Cancer

journal_title

Clinical colorectal cancer

authors

Nozawa H,Ishihara S,Kawai K,Hata K,Kiyomatsu T,Tanaka T,Nishikawa T,Otani K,Yasuda K,Sasaki K,Kaneko M,Murono K

doi

10.1016/j.clcc.2017.10.002

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

e91-e97

issue

1

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(17)30057-9

journal_volume

17

pub_type

杂志文章

相关文献

Clinical Colorectal Cancer文献大全
  • Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

    abstract：INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.09.006

    authors： Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

    更新日期：2019-03-01 00:00:00

  • Current approaches to first-line treatment of advanced colorectal cancer.

    abstract：:The multiplicity of chemotherapy regimens currently available to treat colorectal cancer in the first-line setting precludes the identification of a single standard regimen for front-line therapy. The previous standard, 5-fluorouracil (5-FU), formerly the only agent with any significant activity against colorectal can...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2004.s.002

    authors： Goldberg RM

    更新日期：2004-06-01 00:00:00

  • Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

    abstract：:Significant advances have been made with respect to our understanding of the critical role of agents targeting angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target angiogenic signaling, bevacizumab, ziv-aflibercept, and regorafenib, provides strong evidence ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2014.02.001

    authors： Lee JJ,Chu E

    更新日期：2014-09-01 00:00:00

  • An adverse interaction between warfarin and fluoropyrimidines revisited.

    abstract：:Regimens based on flouropyrimidines (eg, 5-fluorouracil [5-FU] and capecitabine) are the mainstay of chemotherapy for several malignancies, including colon, pancreatic, upper gastrointestinal, and breast cancers. Warfarin is one of the most commonly used oral anticoagulants. Patients receiving concomitant capecitabine...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2005.n.028

    authors： Saif MW

    更新日期：2005-09-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract：:The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2015.05.006

    authors： Lee MS,Kopetz S

    更新日期：2015-12-01 00:00:00

  • Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.

    abstract：BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 ye...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.07.005

    authors： Vatandoust S,Price TJ,Ullah S,Roy AC,Beeke C,Young JP,Townsend A,Padbury R,Roder D,Karapetis CS

    更新日期：2016-03-01 00:00:00

  • Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.

    abstract：BACKGROUND:Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sa...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2017.09.006

    authors： Siena S,Rivera F,Taieb J,Peeters M,Prenen H,Koukakis R,Demonty G,Köhne CH

    更新日期：2018-03-01 00:00:00

  • Preclinical data targeting vascular endothelial growth factor in colorectal cancer.

    abstract：:Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2004.s.009

    authors： Ellis LM

    更新日期：2004-10-01 00:00:00

  • Targeted therapy in colorectal cancer.

    abstract：:Adjuvant therapy can reduce the risk of disease recurrence in patients with stage II-IV colorectal cancer. Recently, 3 monoclonal antibodies have been shown to improve clinical outcome in this group of patients. Bevacizumab is an antiangiogenesis agent that has been shown in clinical and preclinical models to reverse ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2007.n.004

    authors： Wadler S

    更新日期：2007-01-01 00:00:00

  • Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.

    abstract：BACKGROUND:Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y r...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2011.12.002

    authors： Martin LK,Cucci A,Wei L,Rose J,Blazer M,Schmidt C,Khabiri H,Bloomston M,Bekaii-Saab T

    更新日期：2012-09-01 00:00:00

  • Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

    abstract：BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.08.003

    authors： Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

    更新日期：2016-03-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract：PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/ccc.2005.n.021

    authors： Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期：2005-07-01 00:00:00

  • Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

    abstract：BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.009

    authors： Tosi F,Sartore-Bianchi A,Lonardi S,Amatu A,Leone F,Ghezzi S,Martino C,Bencardino K,Bonazzina E,Bergamo F,Fenocchio E,Martinelli E,Troiani T,Siravegna G,Mauri G,Torri V,Marrapese G,Valtorta E,Cassingena A,Cappello G

    更新日期：2020-12-01 00:00:00

  • Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.

    abstract：BACKGROUND:As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). PATIENTS AND METHODS:The BC cancer agency (BCCA) ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2011.03.004

    authors： Renouf DJ,Lim HJ,Speers C,Villa D,Gill S,Blanke CD,O'Reilly SE,Kennecke H

    更新日期：2011-06-01 00:00:00

  • Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

    abstract：:Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2006.s.005

    authors： von Mehren M

    更新日期：2006-11-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract：:Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2010.s.006

    authors： Stein S,Cohen DJ,Hochster HS

    更新日期：2010-06-01 00:00:00

  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

    abstract：BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2018.06.002

    authors： Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

    更新日期：2018-12-01 00:00:00

  • Therapeutic Evaluation of Biofeedback Therapy in the Treatment of Anterior Resection Syndrome After Sphincter-Saving Surgery for Rectal Cancer.

    abstract：BACKGROUND:Anterior resection syndrome (ARS) is common after sphincter-saving surgery for rectal cancer. It includes changes in the frequency and urgency of bowel movements and fecal incontinence. The therapeutic efficacy of biofeedback on ARS is unclear. We sought to evaluate the effectiveness of biofeedback therapy i...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.11.002

    authors： Liang Z,Ding W,Chen W,Wang Z,Du P,Cui L

    更新日期：2016-09-01 00:00:00

  • Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

    abstract：:This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2004.n.017

    authors： Kuppens IE,Beijnen J,Schellens JH

    更新日期：2004-09-01 00:00:00

  • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

    abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.08.003

    authors： Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

    更新日期：2020-08-19 00:00:00

  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

    abstract：PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2010.n.021

    authors： Lubner SJ,Loconte NK,Holen KD,Schelman W,Thomas JP,Jumonville A,Eickhoff JC,Seo S,Mulkerin DL

    更新日期：2010-07-01 00:00:00

  • Intussusception in colorectal cancer.

    abstract：:Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2008.n.028

    authors： Chand M,Bradford L,Nash GF

    更新日期：2008-05-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract：:Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2008.n.015

    authors： Moosmann N,Heinemann V

    更新日期：2008-03-01 00:00:00

  • Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

    abstract：BACKGROUND:No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-β receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.03.006

    authors： Hanna DL,Loupakis F,Yang D,Cremolini C,Schirripa M,Li M,Matsusaka S,Berger MD,Miyamoto Y,Zhang W,Ning Y,Antoniotti C,Salvatore L,Moran M,Zeger G,Astrow SH,Falcone A,Lenz HJ

    更新日期：2018-09-01 00:00:00

  • AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.

    abstract：BACKGROUND:The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In the context of a prospective single-arm trial (NC...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clcc.2018.06.003

    authors： Pentheroudakis G,Kotoula V,Koliou GA,Karavasilis V,Samantas E,Aravantinos G,Kalogeropoulou L,Souglakos I,Kentepozidis N,Koumakis G,Sgouros J,Zarkavelis G,Efstratiou I,Laschos K,Petraki C,Tikas I,Poulios C,Voutsina A,G

    更新日期：2018-12-01 00:00:00

  • The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

    abstract：BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2011.06.004

    authors： Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

    更新日期：2011-12-01 00:00:00

  • Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.

    abstract：BACKGROUND:Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD). The relationship between the 2 diseases is still unclear, and the impact of DD in patients diagnosed with CC on disease-free survival (DFS) and overall survival (OS) is unknown. N...

    journal_title：Clinical colorectal cancer

    pub_type： 临床试验,杂志文章

    doi：10.3816/ccc.2006.n.031

    authors： Soran A,Harlak A,Wilson JW,Nesbitt L,Lembersky BC,Wienad HS,O'Connell MJ

    更新日期：2006-07-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.05.011

    authors： Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期：2020-09-01 00:00:00

  • Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.

    abstract：BACKGROUND:Initial treatment with either neoadjuvant chemoradiation (CRT) or induction FOLFOX (5-Fluorouracil, leucovorin, and oxaliplatin) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer. We compared patient-reported outcomes (PRO) during CRT in patients who had receive...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2019.04.001

    authors： Ng SY,Colborn KL,Cambridge L,Cercek A,Reidy-Lagunes DL,Segal N,Stadler Z,Saltz LB,Paty PB,Guillem J,Weiser MR,Nash G,Garcia-Aguilar J,Goodman KA

    更新日期：2019-09-01 00:00:00

  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

    abstract：BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.08.002

    authors： Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

    更新日期：2018-12-01 00:00:00